Detail akcie Ipsen online

Business Summary: Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Ipsen SA revenues increased 5% to EUR3.31B. Net income before extraordinary items increased 4% to EUR617.1M. Revenues reflect Rare Diseases segment increase from EUR41.1M to EUR117M, Neurosciences segment increase of 11% to EUR659.3M, Rest Of The World segment increase of 10% to EUR829.1M, Europe segment increase of 2% to EUR1.26B.